115 related articles for article (PubMed ID: 3755713)
1. Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios.
Deacon JM; Holliday SB; Ahmed I; Jenkins TC
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1087-90. PubMed ID: 3755713
[TBL] [Abstract][Full Text] [Related]
2. High uptake of RSU 1069 and its analogues melanotic melanomas.
Walling JM; Deacon J; Holliday S; Stratford IJ
Cancer Chemother Pharmacol; 1989; 24(1):28-32. PubMed ID: 2541936
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
Walton MI; Workman P
Cancer Chemother Pharmacol; 1988; 22(4):275-81. PubMed ID: 3168141
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.
Workman P; Walton MI
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1307-10. PubMed ID: 6547936
[TBL] [Abstract][Full Text] [Related]
5. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
Adams GE; Ahmed I; Sheldon PW; Stratford IJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1653-6. PubMed ID: 6548211
[TBL] [Abstract][Full Text] [Related]
6. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
Walling J; Stratford IJ; Adams GE; Stephens MA
Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Apr; 53(4):641-9. PubMed ID: 3258298
[TBL] [Abstract][Full Text] [Related]
7. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Cole S; Stratford IJ; Adams GE; Fielden EM; Jenkins TC
Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
[TBL] [Abstract][Full Text] [Related]
8. Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analogues.
Walling JM; Stratford IJ; Adams GE; Silver AR; Ahmed I; Jenkins TC; Fielden EM
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1083-6. PubMed ID: 3755712
[TBL] [Abstract][Full Text] [Related]
9. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069.
Horwich A; Holliday SB; Deacon JM; Peckham MJ
Br J Radiol; 1986 Dec; 59(708):1238-40. PubMed ID: 3542110
[No Abstract] [Full Text] [Related]
10. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor.
Chaplin DJ; Durand RE; Stratford IJ; Jenkins TC
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1091-5. PubMed ID: 3755714
[TBL] [Abstract][Full Text] [Related]
11. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Cole S; Stratford IJ; Bowler J; Nolan J; Wright EG; Lorimore SA; Adams GE
Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
[TBL] [Abstract][Full Text] [Related]
12. Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo.
Ahmed I; Jenkins TC; Walling JM; Stratford IJ; Sheldon PW; Adams GE; Fielden EM
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1079-81. PubMed ID: 3755711
[TBL] [Abstract][Full Text] [Related]
13. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
Siemann DW
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1115-8. PubMed ID: 2703392
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger M; Workman P
Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
[TBL] [Abstract][Full Text] [Related]
15. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
Stratford IJ; Adams GE; Godden J; Howells N
Int J Radiat Biol; 1989 Mar; 55(3):411-22. PubMed ID: 2564037
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic transforming potential of nitroimidazole radiosensitizers.
Hall EJ; Hei TK
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
[TBL] [Abstract][Full Text] [Related]
17. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.
Adams GE; Ahmed I; Sheldon PW; Stratford IJ
Br J Cancer; 1984 May; 49(5):571-7. PubMed ID: 6547051
[TBL] [Abstract][Full Text] [Related]
18. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
Cole S; Stratford IJ; Fielden EM; Adams GE; Leopold W; Elliott W; Suto M; Sebolt-Leopold J
Int J Radiat Oncol Biol Phys; 1992; 22(3):545-8. PubMed ID: 1735694
[TBL] [Abstract][Full Text] [Related]
19. The phosphate-group of DNA as a potential target for RSU-1069, a nitroimidazole-aziridine radiosensitizer.
Silver AR; O'Neill P; Jenkins TC; McNeil SS
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1203-6. PubMed ID: 3755715
[TBL] [Abstract][Full Text] [Related]
20. Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
Kanclerz A; Chapman JD
Int J Radiat Oncol Biol Phys; 1988 Feb; 14(2):309-16. PubMed ID: 2828290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
